rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of the study is to investigate the feasibility, safety, and effect of rTMS on mPFC/dACC activity using a combination of fMRI and clinical outcome measures, when used as an augmentation to CBT. Our hypothesis is that we will meet the following milestones prior to moving forward to the UH3 phase (a clinical trial for CUD). * Feasibility: At least 75% of participants will receive at least 15 out of 20 rTMS sessions with no participants experiencing a study-related serious adverse event * Mechanism: Compared to baseline, after 1 week of rTMS, participants who received active rTMS will demonstrate a 15% decrease in RSFC (resting state functional connectivity) between the DLPFC (dorsolateral prefrontal cortex) and anterior cingulate * Efficacy: During the final 12 weeks of the trial (weeks 2-13), at least 15% of participants who received active rTMS will demonstrate 3 consecutive weeks of abstinence Participants will: * Have two brain MRI scans; * Undergo 1 week of daily rTMS (or sham) treatments (up to 20 sessions), and; * Have 12 weeks of once-weekly cognitive-behavioral therapy for the treatment of cocaine use disorder. Researchers will compare active (real) rTMS to sham (placebo) rTMS. All participants will receive cognitive-behavioral therapy. The former principle investigator, Dr. Derek Blevins, has vacated his position (February 2025), and has transferred the principle investigator role to Dr. John Mariani, the STARS Clinic Director.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 22-65 lat
- •Uzależnienie od kokainy rozpoznane przez lekarza w ostatnim czasie, chęć leczenia
- •Stosowanie kokainy co najmniej 9 dni w ostatnich 28 dniach, minimum raz na tydzień
- •Umiejętność wyrażenia świadomej zgody i uczestniczenia w badaniu
- •Gotowość ograniczenia alkoholu i unikania amfetaminy i niektórych leków bez przepisu
- •Kobiety mogące zajść w ciążę muszą stosować antykoncepcję przez czas badania
✗ Disqualifies
- •Ciężka depresja, zaburzenia afektywne, schizofrenia lub inne zaburzenia psychiczne
- •Ciężkie uzależnienie od alkoholu lub innych substancji (poza papierosami)
- •Historia poważnych problemów podczas odstawienia alkoholu lub benzodiazepin wymagająca hospitalizacji
- •Częste stosowanie leków bez przepisu, które mogą zwiększać ryzyko napadów
- •Znaczące ryzyko samobójstwa oceniane przez lekarza
- •Niestabilne zaburzenia psychiczne wymagające innych leczenia podczas badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 22 Years
- Maximum age
- 65 Years
- Last updated (source)
- August 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
New York State Psychiatric Institute (NYSPI) / Substance Treatment and Research Service (STARS)
New York, United States
Trial contact
Daniel Brooks, LCSW
Amy Mahony, LMHC
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.